Jeanne M Marrazzo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6834808/publications.pdf

Version: 2024-02-01

204 papers

10,928 citations

44069 48 h-index ³⁴⁹⁸⁶ 98

g-index

208 all docs 208 docs citations

208 times ranked

8073 citing authors

#	Article	IF	CITATIONS
1	Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women. New England Journal of Medicine, 2015, 372, 509-518.	27.0	1,094
2	Molecular Identification of Bacteria Associated with Bacterial Vaginosis. New England Journal of Medicine, 2005, 353, 1899-1911.	27.0	1,080
3	Bacterial Communities in Women with Bacterial Vaginosis: High Resolution Phylogenetic Analyses Reveal Relationships of Microbiota to Clinical Criteria. PLoS ONE, 2012, 7, e37818.	2.5	545
4	Sexually transmitted infections: challenges ahead. Lancet Infectious Diseases, The, 2017, 17, e235-e279.	9.1	510
5	Temporal Variability of Human Vaginal Bacteria and Relationship with Bacterial Vaginosis. PLoS ONE, 2010, 5, e10197.	2.5	363
6	Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. New England Journal of Medicine, 2021, 385, 595-608.	27.0	359
7	Targeted PCR for Detection of Vaginal Bacteria Associated with Bacterial Vaginosis. Journal of Clinical Microbiology, 2007, 45, 3270-3276.	3.9	328
8	Characterization of Vaginal Flora and Bacterial Vaginosis in Women Who Have Sex with Women. Journal of Infectious Diseases, 2002, 185, 1307-1313.	4.0	234
9	Diversity of Human Vaginal Bacterial Communities and Associations with Clinically Defined Bacterial Vaginosis. Applied and Environmental Microbiology, 2008, 74, 4898-4909.	3.1	230
10	Metabolic Signatures of Bacterial Vaginosis. MBio, 2015, 6, .	4.1	230
11	The Evolving Facets of Bacterial Vaginosis: Implications for HIV Transmission. AIDS Research and Human Retroviruses, 2019, 35, 219-228.	1.1	188
12	Performance and Cost-Effectiveness of Selective Screening Criteria for Chlamydia trachomatis Infection in Women. Sexually Transmitted Diseases, 1997, 24, 131-141.	1.7	176
13	Single-Dose Zoliflodacin (ETX0914) for Treatment of Urogenital Gonorrhea. New England Journal of Medicine, 2018, 379, 1835-1845.	27.0	148
14	Relationship of Specific Vaginal Bacteria and Bacterial Vaginosis Treatment Failure in Women Who Have Sex with Women. Annals of Internal Medicine, 2008, 149, 20.	3.9	146
15	Bacterial Vaginosis and the Cervicovaginal Immune Response. American Journal of Reproductive Immunology, 2014, 71, 555-563.	1.2	146
16	Genital Human Papillomavirus Infection in Women Who Have Sex with Women. Journal of Infectious Diseases, 1998, 178, 1604-1609.	4.0	144
17	Changes in Vaginal Bacterial Concentrations with Intravaginal Metronidazole Therapy for Bacterial Vaginosis as Assessed by Quantitative PCR. Journal of Clinical Microbiology, 2009, 47, 721-726.	3.9	141
18	Community-Based Urine Screening for Chlamydia trachomatis with a Ligase Chain Reaction Assay. Annals of Internal Medicine, 1997, 127, 796.	3.9	123

#	Article	IF	Citations
19	An Empiric HIV Risk Scoring Tool to Predict HIV-1 Acquisition in African Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, 333-343.	2.1	123
20	Sexual Practices, Risk Perception and Knowledge of Sexually Transmitted Disease Risk Among Lesbian and Bisexual Women. Perspectives on Sexual and Reproductive Health, 2005, 37, 6-12.	3 . 3	117
21	Head-to-Head Multicenter Comparison of DNA Probe and Nucleic Acid Amplification Tests for Chlamydia trachomatis Infection in Women Performed with an Improved Reference Standard. Journal of Clinical Microbiology, 2002, 40, 3757-3763.	3.9	111
22	HIV Prevention in Clinical Care Settings. JAMA - Journal of the American Medical Association, 2014, 312, 390.	7.4	109
23	Genital human papillomavirus infection in women who have sex with women: A review. American Journal of Obstetrics and Gynecology, 2000, 183, 770-774.	1.3	108
24	The Vaginal Microbiome: Current Understanding and Future Directions. Journal of Infectious Diseases, 2016, 214, S36-S41.	4.0	102
25	Extravaginal Reservoirs of Vaginal Bacteria as Risk Factors for Incident Bacterial Vaginosis. Journal of Infectious Diseases, 2012, 205, 1580-1588.	4.0	96
26	Rapid and Profound Shifts in the Vaginal Microbiota Following Antibiotic Treatment for Bacterial Vaginosis. Journal of Infectious Diseases, 2015, 212, 793-802.	4.0	94
27	Interpreting the epidemiology and natural history of bacterial vaginosis: Are we still confused?. Anaerobe, 2011, 17, 186-190.	2.1	93
28	Management of Women with Cervicitis. Clinical Infectious Diseases, 2007, 44, S102-S110.	5 . 8	83
29	Risks for Acquisition of Bacterial Vaginosis Among Women Who Report Sex with Women: A Cohort Study. PLoS ONE, 2010, 5, e11139.	2.5	82
30	Performance of Swabs, Lavage, and Diluents to Quantify Biomarkers of Female Genital Tract Soluble Mucosal Mediators. PLoS ONE, 2011, 6, e23136.	2.5	77
31	Barriers to Bacterial Sexually Transmitted Infection Testing of HIV-Infected Men Who Have Sex With Men Engaged in HIV Primary Care. Sexually Transmitted Diseases, 2015, 42, 590-594.	1.7	7 5
32	Sexual practices, risk perception and knowledge of sexually transmitted disease risk among lesbian and bisexual women. Perspectives on Sexual and Reproductive Health, 2005, 37, 6-12.	3.3	72
33	Distribution of Genital <i>Lactobacillus</i> Strains Shared by Female Sex Partners. Journal of Infectious Diseases, 2009, 199, 680-683.	4.0	71
34	Disclosure of pharmacokinetic drug results to understand nonadherence. Aids, 2015, 29, 2161-2171.	2,2	71
35	More Than Meets the Eye: Associations of Vaginal Bacteria with Gram Stain Morphotypes Using Molecular Phylogenetic Analysis. PLoS ONE, 2013, 8, e78633.	2.5	67
36	Barriers to Infectious Disease Care among Lesbians 1. Emerging Infectious Diseases, 2004, 10, 1975-1978.	4.3	66

#	Article	IF	CITATIONS
37	Risk Factors for Cervicitis among Women with Bacterial Vaginosis. Journal of Infectious Diseases, 2006, 193, 617-624.	4.0	63
38	Prevalence and Risks for Bacterial Vaginosis in Women Who Have Sex With Women. Sexually Transmitted Diseases, 2010, 37, 335-339.	1.7	62
39	<i>Chlamydia trachomatis</i> Infection Among Women Reporting Sexual Activity With Women Screened in Family Planning Clinics in the Pacific Northwest, 1997 to 2005. American Journal of Public Health, 2011, 101, 1284-1290.	2.7	61
40	Sexually Transmitted Infections Among Women Who Have Sex With Women. Clinical Infectious Diseases, 2011, 53, S84-S91.	5.8	60
41	Prevalence and Risk Factors for Infection With Herpes Simplex Virus Type-1 and -2 Among Lesbians. Sexually Transmitted Diseases, 2003, 30, 890-895.	1.7	59
42	Molecular methodology in determining vaginal flora in health and disease: Its time has come. Current Infectious Disease Reports, 2005, 7, 463-470.	3.0	58
43	Bacterial Vaginosis–Associated Bacteria in Men. Sexually Transmitted Diseases, 2013, 40, 944-949.	1.7	56
44	Differences in Cumulative Exposure and Adherence to Tenofovir in the VOICE, iPrEx OLE, and PrEP Demo Studies as Determined via Hair Concentrations. AIDS Research and Human Retroviruses, 2017, 33, 778-783.	1.1	52
45	Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial. Clinical Infectious Diseases, 2019, 68, 803-809.	5.8	52
46	Emerging Sexual Health Issues Among Women Who Have Sex with Women. Current Infectious Disease Reports, 2012, 14, 204-211.	3.0	51
47	Prevalence and risks for bacterial vaginosis in women who have sex with women. Sexually Transmitted Diseases, 2010, 37, 335-9.	1.7	49
48	Characteristics of female sexually transmitted disease clinic clients who report same-sex behaviour. International Journal of STD and AIDS, 2001, 12, 41-46.	1.1	48
49	Predicting chlamydial and gonococcal cervical infection: implications for management of cervicitis. Obstetrics and Gynecology, 2002, 100, 579-584.	2.4	48
50	PrEParing Women to Prevent HIV: An Integrated Theoretical Framework to PrEP Black Women in the United States. Journal of the Association of Nurses in AIDS Care, 2018, 29, 835-848.	1.0	48
51	Urine-Based Screening for Chlamydia trachomatis in Men Attending Sexually Transmitted Disease Clinics. Sexually Transmitted Diseases, 2001, 28, 219-225.	1.7	47
52	Common Complementary and Alternative Therapies for Yeast Vaginitis and Bacterial Vaginosis: A Systematic Review. Obstetrical and Gynecological Survey, 2003, 58, 351-358.	0.4	47
53	Reproductive health history of lesbians: implications for care. American Journal of Obstetrics and Gynecology, 2004, 190, 1298-1304.	1.3	46
54	Effectiveness of Two Tinidazole Regimens in Treatment of Bacterial Vaginosis. Obstetrics and Gynecology, 2007, 110, 302-309.	2.4	46

#	Article	IF	Citations
55	Within the Hidden Epidemic: Sexually Transmitted Diseases and HIV/AIDS Among American Indians and Alaska Natives. Sexually Transmitted Diseases, 2007, 34, 767-777.	1.7	46
56	Divergent adherence estimates with pharmacokinetic and behavioural measures in the MTNâ€003 (VOICE) study. Journal of the International AIDS Society, 2016, 19, 20642.	3.0	45
57	Chlamydia trachomatis infection in asymptomatic men. American Journal of Preventive Medicine, 2003, 24, 36-42.	3.0	44
58	Risk of HIV-1 acquisition among women who use different types of injectable progestin contraception in South Africa: a prospective cohort study. Lancet HIV, the, 2015, 2, e279-e287.	4.7	43
59	Bone Mineral Density Changes Among Young, Healthy African Women Receiving Oral Tenofovir for HIV Preexposure Prophylaxis. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 287-294.	2.1	42
60	Implementation and Operational Research. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 72, e26-e31.	2.1	42
61	A Persistent(ly) Enigmatic Ecological Mystery: Bacterial Vaginosis. Journal of Infectious Diseases, 2006, 193, 1475-1477.	4.0	40
62	Interventions to Prevent Sexually Transmitted Infections, Including HIV Infection. Clinical Infectious Diseases, 2011, 53, S64-S78.	5.8	40
63	Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE Study. Journal of Infectious Diseases, 2016, 213, 335-342.	4.0	40
64	Mucopurulent Cervicitis: No Longer Ignored, but Still Misunderstood. Infectious Disease Clinics of North America, 2005, 19, 333-349.	5.1	38
65	Selective Screening for Chlamydial Infection In Women: A Comparison of Three Sets of Criteria. Family Planning Perspectives, 1997, 29, 158.	0.7	36
66	The Clinical and Economic Consequences of Screening Young Men for Genital Chlamydial Infection. Sexually Transmitted Diseases, 2003, 30, 99-106.	1.7	36
67	The Cost-Effectiveness of Screening Men for Chlamydia trachomatis: A Review of the Literature. Sexually Transmitted Diseases, 2008, 35, S51-S60.	1.7	35
68	Ocular Syphilis: a Clinical Review. Current Infectious Disease Reports, 2016, 18, 36.	3.0	35
69	Tenofovir disoproxil fumarate intravaginal ring for HIV pre-exposure prophylaxis in sexually active women: a phase 1, single-blind, randomised, controlled trial. Lancet HIV,the, 2019, 6, e498-e508.	4.7	35
70	Chlamydial Infections Among Female Adolescents Screened in Juvenile Detention Centers in Washington State, 1998???2002. Sexually Transmitted Diseases, 2006, 33, 63-67.	1.7	34
71	Effect of Sexual Activity on Vaginal Colonization With Hydrogen Peroxide-Producing Lactobacilli and Gardnerella vaginalis. Sexually Transmitted Diseases, 2011, 38, 1137-1144.	1.7	34
72	Behavioral Predictors of Colonization with <i>Lactobacillus crispatus </i> or <i>Lactobacillus jensenii </i> after Treatment for Bacterial Vaginosis: A Cohort Study. Infectious Diseases in Obstetrics and Gynecology, 2012, 2012, 1-6.	1.5	34

#	Article	IF	Citations
73	Age-Disparate Partnerships and Risk of HIV-1 Acquisition Among South African Women Participating in the VOICE Trial. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 70, 212-217.	2.1	34
74	Relationship of Specific Bacteria in the Cervical and Vaginal Microbiotas With Cervicitis. Sexually Transmitted Diseases, 2015, 42, 475-481.	1.7	33
75	Genital Human Papillomavirus Infection in Women Who Have Sex with Women: A Concern for Patients and Providers. AIDS Patient Care and STDs, 2000, 14, 447-451.	2.5	32
76	Hormonal contraceptive use modulates the local inflammatory response to bacterial vaginosis. Sexually Transmitted Infections, 2008, 84, 57-61.	1.9	32
77	Acceptability of Urine-Based Screening for Chlamydia trachomatis in Asymptomatic Young Men: A Systematic Review. Sexually Transmitted Diseases, 2008, 35, S28-S33.	1.7	31
78	A behavioural intervention to reduce persistence of bacterial vaginosis among women who report sex with women: results of a randomised trial. Sexually Transmitted Infections, 2011, 87, 399-405.	1.9	31
79	More Easily Cultivated Than Identified: Classical Isolation With Molecular Identification of Vaginal Bacteria. Journal of Infectious Diseases, 2016, 214, S21-S28.	4.0	30
80	Women's Satisfaction with an IntravaginalLactobacillusCapsule for the Treatment of Bacterial Vaginosis. Journal of Women's Health, 2006, 15, 1053-1060.	3.3	29
81	Re-evaluating Selective Screening Criteria for Chlamydial Infection Among Women in the U.S. Pacific Northwest. Sexually Transmitted Diseases, 2004, 31, 283-289.	1.7	28
82	Women Who Have Sex with Women Living in Low- and Middle-Income Countries: A Systematic Review of Sexual Health and Risk Behaviors. LGBT Health, 2015, 2, 91-104.	3.4	28
83	Evolving issues in understanding and treating bacterial vaginosis. Expert Review of Anti-Infective Therapy, 2004, 2, 913-922.	4.4	27
84	Population-Based Outreach for Chlamydia Screening in Men: Results From a Randomized Trial. Sexually Transmitted Diseases, 2007, 34, 837-839.	1.7	27
85	Sexually transmitted infections in women who have sex with women: who cares?. Sexually Transmitted Infections, 2000, 76, 330-332.	1.9	26
86	Impact of Patient Characteristics on Performance of Nucleic Acid Amplification Tests and DNA Probe for Detection of Chlamydia trachomatis in Women with Genital Infections. Journal of Clinical Microbiology, 2005, 43, 577-584.	3.9	26
87	A Prospective Cohort Study Comparing the Effect of Single-Dose 2 g Metronidazole on Trichomonas vaginalis Infection in HIV-Seropositive Versus HIV-Seronegative Women. Sexually Transmitted Diseases, 2013, 40, 499-505.	1.7	26
88	Rapid Diagnosis of Trichomonas vaginalis by Testing Vaginal Swabs in an Isothermal Helicase-Dependent AmpliVue Assay. Sexually Transmitted Diseases, 2016, 43, 369-373.	1.7	25
89	The fourth generation Alere TM HIV Combo rapid test improves detection of acute infection in MTN-003 (VOICE) samples. Journal of Clinical Virology, 2017, 94, 15-21.	3.1	25
90	Functional Characterization of Class Ia- and Non-Class Ia-Restricted <i>Chlamydia</i> Reactive CD8+ T Cell Responses in Humans. Journal of Immunology, 2003, 171, 4278-4286.	0.8	24

#	Article	IF	Citations
91	Characteristics of female sexually transmitted disease clinic clients who report same-sex behaviour. International Journal of STD and AIDS, 2001, 12, 41-46.	1.1	24
92	Antiviral Activity of Genital Tract Secretions After Oral or Topical Tenofovir Pre-exposure Prophylaxis for HIV-1. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 66, 65-73.	2.1	23
93	A Phase 3, Multicenter, Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of Metronidazole Vaginal Gel 1.3% in the Treatment of Bacterial Vaginosis. Sexually Transmitted Diseases, 2015, 42, 376-381.	1.7	22
94	Mucosal Escherichia coli Bactericidal Activity and Immune Mediators Are Associated With HIV-1 Seroconversion in Women Participating in the HPTN 035 Trial. Journal of Infectious Diseases, 2012, 206, 1931-1935.	4.0	21
95	Variations in Clinical Presentation of Ocular Syphilis: Case Series Reported From a Growing Epidemic in the United States. Sexually Transmitted Diseases, 2016, 43, 519-523.	1.7	21
96	Diversity in the US Infectious Diseases Workforce: Challenges for Women and Underrepresented Minorities. Journal of Infectious Diseases, 2017, 216, S606-S610.	4.0	21
97	Tenofovir Gel for Prevention of Herpes Simplex Virus Type 2 Acquisition: Findings From the VOICE Trial. Journal of Infectious Diseases, 2019, 219, 1940-1947.	4.0	21
98	Dangerous Assumptions: Lesbians and Sexual Death. Sexually Transmitted Diseases, 2005, 32, 570-571.	1.7	20
99	Sexually transmitted infections in the era of antiretroviral-based HIV prevention: Priorities for discovery research, implementation science, and community involvement. PLoS Medicine, 2018, 15, e1002485.	8.4	20
100	Protection and Risk: Male and Female Genital Microbiota and Sexually Transmitted Infections. Journal of Infectious Diseases, 2021, 223, S222-S235.	4.0	20
101	Recent advances in understanding and managing Chlamydia trachomatis infections. F1000prime Reports, 2014, 6, 120.	5.9	19
102	Chlamydia Positivity in Women Screened in Family Planning Clinics: Racial/Ethnic Differences and Trends in the Northwest U.S., 1997–2006. Public Health Reports, 2012, 127, 38-51.	2.5	18
103	Bacteria Associated with Bacterial Vaginosis. New England Journal of Medicine, 2006, 354, 202-203.	27.0	17
104	The Posttrial Effect of Oral Periodic Presumptive Treatment for Vaginal Infections on the Incidence of Bacterial Vaginosis and Lactobacillus Colonization. Sexually Transmitted Diseases, 2012, 39, 361-365.	1.7	17
105	Diagnosis and Management of Bacterial Vaginosis: Summary of Evidence Reviewed for the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infections Treatment Guidelines. Clinical Infectious Diseases, 2022, 74, S144-S151.	5.8	16
106	Lesbian Health Matters: A Pap Test Education Campaign Nearly Thwarted by Discrimination. Health Promotion Practice, 2004, 5, 314-325.	1.6	15
107	Sexual tourism: implications for travelers and the destination culture. Infectious Disease Clinics of North America, 2005, 19, 103-120.	5.1	15
108	Acceptability of Urine-Based Screening for Chlamydia trachomatis to Asymptomatic Young Men and Their Providers. Sexually Transmitted Diseases, 2007, 34, 147-153.	1.7	15

#	Article	IF	CITATIONS
109	Selective Testing Criteria for Gonorrhea among Young Women Screened for Chlamydial Infection: Contribution of Race and Geographic Prevalence. Journal of Infectious Diseases, 2007, 196, 731-737.	4.0	14
110	Vaginal Biofilms and Bacterial Vaginosis: Of Mice and Women. Journal of Infectious Diseases, 2013, 207, 1481-1483.	4.0	14
111	Soluble Immune Mediators and Vaginal Bacteria Impact InnateÂGenital Mucosal Antimicrobial Activity in Young Women. American Journal of Reproductive Immunology, 2015, 74, 323-332.	1.2	14
112	Factors associated with bone mineral density in healthy African women. Archives of Osteoporosis, 2015, 10, 206.	2.4	14
113	Reporting of Adherence in the VOICE Trial: Did Disclosure of Product Nonuse Increase at the Termination Visit?. AIDS and Behavior, 2016, 20, 2654-2661.	2.7	14
114	Oral and Vaginal Tenofovir for Genital Herpes Simplex Virus Type 2 Shedding in Immunocompetent Women: A Double-Blind, Randomized, Cross-over Trial. Journal of Infectious Diseases, 2015, 212, 1949-1956.	4.0	13
115	Perceptions and Experiences with the VOICE Adherence Strengthening Program (VASP) in the MTN-003 Trial. AIDS and Behavior, 2015, 19, 770-783.	2.7	12
116	Validity of self-reported history of Chlamydia trachomatisÂinfection. American Journal of Obstetrics and Gynecology, 2017, 216, 393.e1-393.e7.	1.3	12
117	Reply to Forney et al Journal of Infectious Diseases, 2006, 194, 1469-1470.	4.0	11
118	Chlamydia Positivity in American Indian/Alaska Native Women Screened in Family Planning Clinics, 1997–2004. Sexually Transmitted Diseases, 2008, 35, 753-757.	1.7	11
119	Establishing and Sustaining a Healthy Vaginal Environment: Analysis of Data From a Randomized Trial of Periodic Presumptive Treatment for Vaginal Infections. Journal of Infectious Diseases, 2011, 204, 323-326.	4.0	11
120	Association of Tenofovir (TFV) Detection with Reduced Risk of Herpes Simplex virus Type-2 (HSV-2) Acquisition in the VOICE (MTN 003) Study. AIDS Research and Human Retroviruses, 2014, 30, A31-A31.	1.1	11
121	Antiretroviral Therapy for Prevention of Human Immunodeficiency Virus Infection. Medical Clinics of North America, 2016, 100, 927-950.	2.5	11
122	Risk Factors for Incidence of Sexually Transmitted Infections Among Women in a Human Immunodeficiency Virus Chemoprevention Trial: VOICE (MTN-003). Sexually Transmitted Diseases, 2017, 44, 135-140.	1.7	11
123	Sexually Transmitted Infection Prevalence in Women With HIV: Is There a Role for Targeted Screening?. Sexually Transmitted Diseases, 2018, 45, 762-769.	1.7	11
124	Social harms in female-initiated HIV prevention method research. Aids, 2019, 33, 2237-2244.	2.2	11
125	Vaginal and Extra-Vaginal Bacterial Colonization and Risk for Incident Bacterial Vaginosis in a Population of Women Who Have Sex With Men. Journal of Infectious Diseases, 2022, 225, 1261-1265.	4.0	10
126	Differences in Vaginal Microbiota, Host Transcriptome, and Proteins in Women With Bacterial Vaginosis Are Associated With Metronidazole Treatment Response. Journal of Infectious Diseases, 2021, 224, 2094-2104.	4.0	10

#	Article	IF	CITATIONS
127	Characterizing HIV-Preventive, Plasma Tenofovir Concentrations—A Pooled Participant-level Data Analysis From Human Immunodeficiency Virus Preexposure Prophylaxis Clinical Trials. Clinical Infectious Diseases, 2022, 75, 1873-1882.	5.8	10
128	Routine HIV testing in the context of syndromic management of sexually transmitted infections: outcomes of the first phase of a training programme in Botswana. Sexually Transmitted Infections, 2008, 84, 259-264.	1.9	9
129	Antiretroviral-based HIV prevention strategies for women. Expert Review of Anti-Infective Therapy, 2010, 8, 1177-1186.	4.4	9
130	Sexually Transmitted Infection Prevalence Among Women at Risk for HIV Exposure Initiating Safer Conception Care in Rural, Southwestern Uganda. Sexually Transmitted Diseases, 2020, 47, e24-e28.	1.7	9
131	Neisseria gonorrhoeae. , 2010, , 2753-2770.		9
132	High rates of persistent and recurrent chlamydia in pregnant women after treatment with azithromycin. American Journal of Obstetrics & Synecology MFM, 2020, 2, 100216.	2.6	9
133	Extracts from "Concise Clinical Evidence": Vulvovaginal candidiasis. BMJ: British Medical Journal, 2002, 325, 586-586.	2.3	8
134	Addressing Standards of Care in Resource-Limited Settings. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 65, S10-S14.	2.1	8
135	Improving HIV/STD Prevention in the Care of Persons Living with HIV Through a National Training Program. AIDS Patient Care and STDs, 2014, 28, 15-21.	2.5	8
136	Tenofovir-Based Preexposure Prophylaxis for HIV Infection Among African Women. Obstetrical and Gynecological Survey, 2015, 70, 444-446.	0.4	8
137	Neisseria gonorrhoeae (Gonorrhea). , 2015, , 2446-2462.e3.		8
138	HIV Status and Other Risk Factors for Prevalent and Incident Sexually Transmitted Infection during Pregnancy (2000-2014). Infectious Diseases in Obstetrics and Gynecology, 2019, 2019, 1-8.	1.5	8
139	PrEP service delivery preferences of black Cis-gender women living in the Southern United States. AIDS and Behavior, 2022, 26, 3469-3479.	2.7	8
140	Title is missing!. Obstetrical and Gynecological Survey, 2003, 58, 351-358.	0.4	7
141	Health Care Provider Perceptions of a Sexually Transmitted Infection Self-testing Program in an HIV Care Clinic. Sexually Transmitted Diseases, 2018, 45, 417-421.	1.7	7
142	Intersecting Epidemics: Incident Syphilis and Drug Use in Women Living with HIV in the United States (2005-2016). Clinical Infectious Diseases, 2020, 71, 2405-2413.	5.8	7
143	Sexual Practices, Risk Perception and Knowledge of Sexually Transmitted Disease Risk Among Lesbian and Bisexual Women. Perspectives on Sexual and Reproductive Health, 2005, 37, 6-12.	3.3	7
144	HIV Prevention: Opportunities and Challenges. Topics in Antiviral Medicine, 2017, 24, 123-126.	0.1	7

#	Article	IF	CITATIONS
145	BIOMEDICAL PREVENTION OF HIV IN WOMEN: CHALLENGES AND APPROACHES, WITH PARTICULAR REFERENCE TO THE VAGINAL MICROBIOME. Transactions of the American Clinical and Climatological Association, 2018, 129, 63-73.	0.5	7
146	A qualitative exploration to understand barriers and facilitators to daily oral PrEP uptake and sustained adherence among HIVâ€negative women planning for or with pregnancy in rural Southwestern Uganda. Journal of the International AIDS Society, 2022, 25, e25894.	3.0	7
147	Cervical Specimen Order and Performance Measures of Chlamydia trachomatis Diagnostic Testing. Journal of Clinical Microbiology, 2005, 43, 5295-5297.	3.9	6
148	Expanding the Spectrum of Pathogens in Urethritis: Implications for Presumptive Therapy?. Clinical Infectious Diseases, 2007, 45, 872-874.	5 . 8	6
149	Preferred Characteristics of Vaginal Microbicides in Women with Bacterial Vaginosis. Journal of Women's Health, 2009, 18, 1163-1167.	3.3	6
150	Levels of Genital Tract Defensins and Cytokines Differ between <scp>HIV</scp> â€Uninfected <scp>US</scp> and African Women. American Journal of Reproductive Immunology, 2015, 74, 313-322.	1.2	6
151	Prevention of Sexually Transmitted Diseases in HIV-Infected Individuals. Current HIV/AIDS Reports, 2017, 14, 41-46.	3.1	6
152	Decreasing High-risk Exposures for Healthcare Workers Through Universal Masking and Universal Severe Acute Respiratory Syndrome Coronavirus 2 Testing on Entry to a Tertiary Care Facility. Clinical Infectious Diseases, 2021, 73, e3113-e3115.	5. 8	6
153	Prevalent human papillomavirus infection increases the risk of HIV acquisition in African women: advancing the argument for human papillomavirus immunization. Aids, 2022, 36, 257-265.	2.2	6
154	Impact of new sexually transmitted disease diagnostics on clinical practice and public health policy. Current Infectious Disease Reports, 2001, 3, 147-151.	3.0	5
155	Contraceptive Use and Pregnancy Incidence Among Women Participating in an HIV Prevention Trial. Journal of Women's Health, 2017, 26, 670-676.	3.3	5
156	HIV and COVID-19: Lessons From HIV and STI Harm Reduction Strategies. Current HIV/AIDS Reports, 2021, 18, 261-270.	3.1	5
157	Prevalence of and Factors Associated With Genital and Extragenital Chlamydia and Gonorrhea Among Transgender Women in HIV Care in the United States, 2005 to 2016. Sexually Transmitted Diseases, 2021, 48, 410-416.	1.7	5
158	Influence of dapivirine vaginal ring use on cervicovaginal immunity and functional microbiome in adolescent girls. Aids, 2021, 35, 369-380.	2.2	5
159	Cesarean delivery in women with genital herpes in Washington state, 1989-1991. Infectious Diseases in Obstetrics and Gynecology, 1997, 5, 29-35.	1.5	4
160	Emerging issues in management of sexually transmitted diseases in HIV infection. Current Infectious Disease Reports, 2007, 9, 518-30.	3.0	4
161	Screening and Management of Genital Chlamydial Infections. Infectious Disease Clinics of North America, 2013, 27, 739-753.	5.1	4
162	STIs Among Women Who Have Sex with Women. , 2017, , 233-246.		4

#	Article	IF	Citations
163	Editorial Commentary: Sexual Networks, Sex Hormones, and Recurrent Bacterial Vaginosis: Not Such Strange Bedfellows. Clinical Infectious Diseases, 2013, 56, 787-789.	5.8	3
164	American Sexually Transmitted Diseases Association and the Thomas Parran Award. Sexually Transmitted Diseases, 2013, 40, 275-276.	1.7	3
165	Development of a Risk Scoring Tool to Predict HIV-1 Acquisition in African Women. AIDS Research and Human Retroviruses, 2014, 30, A214-A214.	1.1	3
166	A Shot in the Arm for HIV Prevention? Recent Successes and Critical Thresholds. AIDS Research and Human Retroviruses, 2015, 31, 1055-1059.	1.1	3
167	Use of the dapivirine vaginal ring and effect on cervical cytology abnormalities. Aids, 2020, 34, 559-567.	2.2	3
168	Evaluation of the National Sexually Transmitted Disease Curriculum: Reach, Utilization, and Engagement. Sexually Transmitted Diseases, 2020, 47, 412-418.	1.7	3
169	ECHO: context and limitations. Lancet, The, 2020, 395, e23.	13.7	3
170	Genetic Variation in Toll-Like Receptor 5 and Colonization with Flagellated Bacterial Vaginosis-Associated Bacteria. Infection and Immunity, 2021, 89, .	2.2	3
171	What's new in sexually transmitted infections in the HIV care setting: focus on syphilis and gonorrhea. Topics in Antiviral Medicine, 2014, 22, 698-701.	0.1	3
172	Elusive aetiology of bacterial vaginosis. Do lesbians have a clue?. Sexually Transmitted Infections, 2007, 83, 424-425.	1.9	2
173	Advancing Care for Lesbian, Gay, Bisexual, and Transgender Persons: Enough Already?. Annals of Internal Medicine, 2015, 163, 143-144.	3.9	2
174	P239â€Genital HSV-2 suppression is not associated with alterations in the vaginal microbiome: a one-way, cross-over study. , 2019, , .		2
175	Prevalence and Incidence of Sexually Transmitted Infection in Injectable Progestin Contraception Users in South Africa. Frontiers in Reproductive Health, 2021, 3, .	1.9	2
176	Screening for Chlamydia and Gonorrhea. JAMA - Journal of the American Medical Association, 2021, 326, 913.	7.4	2
177	Annals On Call - Protecting Health Care Workers From COVID-19. Annals of Internal Medicine, 2020, 172, OC1.	3.9	2
178	Even NHANES Evolves: Some Surprising Findings About Women Who Have Sex With Women. Sexually Transmitted Diseases, 2010, 37, 414-415.	1.7	2
179	Bacterial Vaginosis. , 2013, , 463-498.		1
180	Syphilis? An Unusual Cause of Surgical Emergency in a Human Immunodeficiency Virus-Infected Man. Open Forum Infectious Diseases, 2015, 2, ofv094.	0.9	1

#	Article	IF	CITATIONS
181	P588â€A multi-site comparative study to understand sources of variability in studies of the vaginal microbiota. , 2019, , .		1
182	Behavioral Counseling for Sexually Transmitted Infection Risk Reduction. JAMA - Journal of the American Medical Association, 2020, 324, 640.	7.4	1
183	Cervicitis: Balancing the Goals of Empiric Therapy and Antimicrobial Stewardship to Improve Women's Health. Sexually Transmitted Diseases, 2020, 47, 387-388.	1.7	1
184	Molecular Characterization of Microbes in the Female Upper Genital Tract: A Valiant Quest to "Redefine―Pelvic Inflammatory Disease. Journal of Infectious Diseases, 2021, 224, S36-S38.	4.0	1
185	Enhancing Women's Sexual Health: Prevention Measures in Diverse Populations of Women. , 2013, , 197-219.		1
186	†I still desire to have a child†: a qualitative analysis of intersectional HIV- and childlessness-related stigma in rural southwestern Uganda. Culture, Health and Sexuality, 2023, 25, 143-158.	1.8	1
187	Bacterial Sexually Transmitted Infection Incidence Among Southern Men Who Have Sex With Men With Human Immunodeficiency Virus in the Treatment as Prevention Era, 2014–2019. Clinical Infectious Diseases, 2022, 75, 1446-1448.	5.8	1
188	What's Old Is New: the Evolution of Lymphogranuloma Venereum Proctitis in Persons Living with HIV. Current Infectious Disease Reports, 2022, 24, 97-104.	3.0	1
189	Superficial Hepatic Capsular Lesions in a Systemically Ill Young Woman. Sexually Transmitted Diseases, 2007, 34, 139-140.	1.7	O
190	Sexually Transmitted Infections. Infectious Disease Clinics of North America, 2013, 27, ix-x.	5.1	0
191	Introduction to the special issue highlighting Anaerobe 2012. Anaerobe, 2013, 24, 85-86.	2.1	O
192	Topical Microbicides for Human Immunodeficiency Virus and Sexually Transmitted Disease Prevention. , 2013, , 213-227.		0
193	Syphilis in Women. , 2013, , 461-471.		O
194	Chlamydia trachomatisInfection among Sexual Minorities. Issues in Infectious Diseases, 2013, , 142-150.	0.1	0
195	Uptake of HBV Vaccination and Incident HBV Infection in Women of Reproductive Age and at Risk of HIV-1 Infection in the VOICE (MTN 003) Study. AIDS Research and Human Retroviruses, 2014, 30, A278-A278.	1.1	O
196	Review: Self-collected samples are less accurate for HPV testing than clinician-collected samples. Annals of Internal Medicine, 2014, 161, JC11.	3.9	0
197	Management of Gonorrhea. , 2017, , 592-596.e1.		0
198	P728â€Correlates of syphilis in women living with and without HIV in the US women's interagency HIV study (WIHS)., 2019, , .		0

#	Article	IF	CITATIONS
199	P369â€Incidence of vaginal infections in kenyan women randomized to continuous or cyclic contraceptive ring (CVR). , 2019, , .		O
200	Recent Developments in Biomedical Issues in Sexually Transmitted Infections: Implications for Behavioral Parameters of Interest. Sexually Transmitted Diseases, 2019, 46, e65-e67.	1.7	0
201	Walter E. Stamm, MD, 1945–2009. Sexually Transmitted Diseases, 2010, 37, 281-282.	1.7	O
202	Introduction to Sexually Transmitted Infections. , 2012, , 300-302.		0
203	Annals On Call - Diagnosing SARS-CoV-2 Infection: Symptoms or No Symptoms?. Annals of Internal Medicine, 2020, 173, OC1.	3.9	О
204	Population-level correlation between incidence of curable sexually transmitted infections and HIV-1 among African women participating in HIV-1 pre-exposure prophylaxis trials. Journal of Infectious Diseases, 0, , .	4.0	0